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ABSTRACT
Multiparametric Magnetic Resonance Imaging has been increasingly used for detection, localization and staging of prostate cancer 
over the last years. It combines high-resolution T2 Weighted-Imaging and at least two functional techniques, which include Dynamic 
Contrast–Enhanced Magnetic Resonance Imaging, Diffusion-Weighted Imaging, and Magnetic Resonance Imaging Spectroscopy. 
Although the combined use of a pelvic phased-array and an Endorectal Coil is considered the state-of-the-art for Magnetic Resonance 
Imaging evaluation of prostate cancer, Endorectal Coil is only absolute mandatory for Magnetic Resonance Imaging Spectroscopy at 
1.5 T. Sensitivity and specificity levels in cancer detection and localization have been improving with functional technique implementation, 
compared to T2 Weighted-Imaging alone. It has been particularly useful to evaluate patients with abnormal PSA and negative biopsy. 
Moreover, the information added by the functional techniques may correlate to cancer aggressiveness and therefore be useful to select 
patients for focal radiotherapy, prostate sparing surgery, focal ablative therapy and active surveillance. However, more studies are 
needed to compare the functional techniques and understand the advantages and disadvantages of each one. This article reviews the 
basic principles of prostatic mp-Magnetic Resonance Imaging, emphasizing its role on detection, staging and active surveillance of 
prostate cancer.
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RESUMO
A Ressonância Magnética Multiparamétrica tem sido crescentemente utilizada na detecção, localização e estadiamento do cancro 
da próstata. Combina sequências T2 de alta-resolução com pelo menos duas técnicas funcionais, que incluem o estudo dinâmico 
pós-gadolínio, a difusão e a espectroscopia. O protocolo ideal aconselha a utilização combinada de uma antena de superfície e 
uma endorectal; contudo, a antena endorectal é apenas obrigatória para a realização de espectroscopia em aparelhos de 1,5 T. 
Os níveis de sensibilidade e especificidade na detecção e localização do cancro da próstata têm aumentado com a inclusão das 
técnicas funcionais, quando comparados com as sequências T2 isoladas, o que é particularmente vantajoso em doentes que têm 
biópsia negativa, apesar de níveis de PSA persistentemente elevados. Para além disso, a informação adicionada pelas técnicas 
funcionais aparenta correlacionar-se com a agressividade tumoral, podendo tornar-se útil na selecção de doentes radioterapia focal, 
cirurgias conservadoras, terapias de ablação focal e vigilância activa. Contudo, são necessários mais estudos para comparar as várias 
técnicas funcionais e compreender as vantagens e desvantagens de cada uma. Este artigo pretender rever os princípios básicos da 
Ressonância Magnética prostática multiparamétrica, enfatizando o seu papel na detecção, estadiamento e vigilância activa do cancro 
da próstata.
Palavras-chave: Imagem de Difusão por Ressonância Magnética; Neoplasias da Próstata; Ressonância Magnética.
INTRODUCTION
 Magnetic Resonance Imaging (MRI) has been consid-
ered a primary non-invasive imaging tool for the evalua-
tion of the prostate gland on the basis of its high soft tissue 
contrast.1-6 Its use for detection, localization and staging of 
prostate cancer has been increasing over the last years; 
in many centers, it has been essentially used when there’s 
high cancer suspicion despite negative transrectal ultra-
sound (TRUS) guided biopsy findings.7,8 Actually, patients 
with abnormal PSA and negative biopsy represent a partic-
ular population, which simultaneously needs a high sensi-
tivity evaluation (able to accurately pinpoint cancers missed 
at biopsy) and an imaging tool with high negative predictive 
value (in order to avoid an unnecessary repeat biopsy).9
 The value of MRI on prostate cancer has however 
been extended to cases of recurrence suspicion, active 
surveillance, refused biopsy, MRI-guided biopsy, and also 
MRI-US fusion technology to improve the accuracy of US-
guided biopsies.6,10-15
 Although morphological MRI including T1 and T2 
weighted-imaging (WI) has been widely used for the 
pretreatment study of prostate cancer, this technique 
has some limitations and improvement in sensitivity and 
specificity for cancer detection and localization may be 
achieved in combination with functional techniques such as 
dynamic contrast–enhanced MR imaging (DCE), diffusion-
weighted imaging (DWI), and MR spectroscopy (MRS). The 
combination of T2WI with at least two of these techniques is 
known as multiparametric MRI (mp-MRI).2,3, 6,16-18
 Optimal MR imaging for detection and local staging 
of prostate cancer requires the use of an endorectal coil 
(ERC) combined with a pelvic phased-array coil (PPA) with 
a minimum of 16 channels, on a magnet with a field strength 
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of at least 1.5 Tesla (T). Prostate imaging at 3 T benefits 
from higher signal to noise ratios (SNR), improving image 
resolution and acquisition speed without the use of ERC; 
however, some technical limitations related to susceptibility 
artifacts and inhomogeneity of the magnetic field may exist, 
and further research is needed.1,6,7
 One of the advantages of ERC is the significant 
increase in capsular delineation, visualization of the 
neurovascular bundle (facilitating nerve-sparing decisions) 
and rectoprostatic angle, which may not only improve the 
general staging performance (reducing overstaging), but 
also accurately delineate cancer foci in the planning of 
intensity-modulated radiation therapy and enable radiation 
boosting to areas within the prostate.19,20 The levels of 
sensitivity and specificity are variable and depend on the 
centers and the studies, which reflect the differences on 
expertise, equipment, study protocols, diagnostic criteria 
and accuracy of pathologic correlations.2 
 Despite the advantages of the ERC, there’s no absolute 
consensus about it and some authors suggest that its use 
might not be mandatory when the main interest is tumor 
detection and localization, consequently saving time and 
costs, and probably causing less distortion of prostate gland. 
Moreover, the use of a PPA alone for signal reception would 
cause less discomfort for the patient.3,9,19 According to recent 
guidelines from ESUR (European Society of Urogenital 
Radiology), despite the combined use of a PPA and an 
ECR constitutes the state-of-the-art for MRI evaluation of 
prostate cancer, ECR is only absolute mandatory for MR 
spectroscopy (MRS) at 1.5 T, remaining optional at 3 T and 
for other techniques at 1.5 T.6
 At our institution, we perform mp-MRI on a 1.5 T body 
scanner (Magneton Avanto; Siemens) with a 33 mT/m 
maximum attainable amplitude using an eight channel PPA. 
The study of the pelvis includes an axial turbo spin-eco T1WI 
imaging for nodal disease and postbiopsy intraglandular 
hemorrhage detection (5 mm; gap 1.0 mm; repetition time 
[TR] 450 ms; eco time [TE] 7.9 ms; FOV 40 cm; matrix 269 
x 384), and also an axial Blade T2WI with fat saturation 
(FS) (5 mm; gap 1.0 mm; TR 4760 ms; TE 120 ms; FOV 
36 cm; number of blades 20) which improves nodal disease 
and bone metastasis detection. With regard to the prostate 
gland study, we perform a set of axial, coronal and sagital 
high-resolution T2WI (3 mm; gap 0.6 mm; TR 4000 ms; TE 
103 ms; FOV 20 cm; matrix 310 x 320). An axial DWI is 
performed with b factors of 50, 800, 1000 and 1200 s/mm2 
(3.5 mm; gap 0.7 mm; TR 5100 ms; TE 88 ms; FOV 45 
cm; matrix 150 x 192). The DCE-MRI is performed with an 
axial fat-saturated 3D Vibe T1W MR sequence (26 slabs; 
slice oversampling 23%, dist factor 20%; 3.5 mm; TR 4.84 
ms; TE 1.69 ms; FOV 26 cm; matrix 138 x 192), after bolus 
injection of gadoterate meglumine, with a dose of 0.2 mmol/
kg of body weight.
MR Imaging Appearance of Normal Prostate Anatomy
 MRI may depict the zonal anatomy of the prostate 
with great detail due to its high spatial resolution, superior 
contrast resolution, multiplanar capability, and large field of 
view.3,21
 On T1WI, generally obtained only in the axial plane, the 
prostate demonstrates homogeneous low-to-medium signal 
intensity and the zonal anatomy is impossible to discern. In 
contrast, T2WI should be obtained in three planes (axial, 
coronal and sagittal) and is able to depict the zonal anatomy 
(Fig. 1). The peripheral zone, which represents the major 
glandular component of the prostate and composes 70% 
of the prostate in healthy young men, appears high in 
signal on T2WI, whereas the central gland (CG) has lower 
signal intensity because of its compactly arranged smooth 
muscle and loose glandular tissue. The CG includes the 
transitional zone (TZ), which constitutes only about 5% of 
the glandular prostate, and central-periurethral (CZ) zone, 
which makes up about 25% of the glandular prostate. The 
anterior fibromuscular stroma also has low signal intensity 
on T2WI.1,2,7,16,21
 The peripheral and transition zones are separated by a 
visible linear boundary often referred as pseudocapsule or 
surgical capsule. The true prostate capsule surrounds the 
peripheral zone and appears as a hypointense rim in T2WI. 
(Fig. 1) The neurovascular bundles are seen posterolateral 
to the prostate capsule and possess both high and low 
signal intensity foci. The seminal vesicles appear as 
hyperintense on T2WI, whereas the paired vas deferens are 
low in signal intensity. The distal prostatic urethra appears 
as a low-signal-intensity ring in the lower prostate, but the 
proximal urethra is rarely identifiable.1,7,16,21
MR Imaging Appearance of Prostate Cancer
 T2WI has been most effective for peripheral tumors, 
 
Figure 1 - Axial T2WI depicts the normal zonal anatomy. The pe-
ripheral zone appear hyperintense and homogeneous (arrow), 
clearly separated from the central gland by a pseudocapsule (ar-
rowhead). A true hypointense capsule rims the entire gland. In this 
case, some features of benign hyperplasia are seen: heteroge-
neous transitional and central zones, with some intermediate signal 
intensity nodules circumscribed by hypointense halos (open arrow). 
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Figure 2 - Images in a 76-year-old man with persistent high PSA level of 11 ng/mL and an initial negative biopsy. Axial and sagittal T2WI 
(A,B) show an 11 mm hypointense nodule within the right peripheral zone (arrows). The suspicious area demonstrates early enhancement 
on DCE (C) and the obtained time–signal intensity curve (x-axis, time in seconds; y-axis, signal intensity in mean percentage) (D) shows 
a moderate washout following the fast and high peak enhancement. The second biopsy, under cognitive MR-TRUS fusion, revealed an 
adenocarcinoma (Gleason score of 6).
which accounts for 70% of prostate adenocarcinomas. 
On T2WI, tumors usually appear as low signal round or 
ill-defined areas within the normal high-signal intensity 
peripheral zone (Fig.s 2a, 2b, 3a). In contrast, tumors and 
great part of prostatic abnormalities are not identified on 
T1WI; however, this sequence may be advantageous by 
showing post-biopsy hemorrhage, which is almost always 
hyperintense in relation to the normal parenchyma (Fig. 
6b).1-3,7,16,18,21 
 In the transition and central zones, which accounts 
respectively for 20% and 10% of adenocarcinomas, 
T2WI shows significant limitations for depicting cancer, 
because cancer and normal tissue both have low signal 
intensity.18,22 Nevertheless, it is also possible to detect 
cancer in the transition zone, especially when conventional 
MRI is combined with MR spectroscopic imaging and other 
functional modalities.1,7,16,21 Using the classic morphological 
MRI, there are some findings that may support the 
diagnosis of a central prostate tumor, like the existence of 
a homogeneous low-signal intensity region in the transition 
zone (Fig. 5a), poorly defined or spiculated lesion margins, 
the lack of the typical low-signal-intensity rim seen in benign 
adenomatous nodules, the interruption of the surgical 
pseudocapsule, lenticular shape (while benign nodules 
are usually round) and urethral or anterior fibromuscular 
stromal invasion.1,3,7,22,23 
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Figure 3 - Images in a 73-year-old man with PSA level of 18,4 ng/mL and biopsy-proven adenocarcinoma with Gleason score of 7. Axial 
T2WI (A) shows a 10 mm hypointense suspicious nodule within the left peripheral zone (arrows). The lesion appears as bright and dark on 
corresponding raw diffusion weighted (B) and apparent diffusion coefficient (ADC) maps (C), respectively (arrows). In the right peripheral 
zone, a smaller tumoral focus may be seen, sharing the same characteristics on T2WI, DWI, and ADC map (arrowheads). DCE images 
(D,E) demonstrate enhancement of the tumor focus. Two regions of interest were placed and time–signal intensity curves were obtained 
(x-axis, time in seconds; y-axis, signal intensity in mean percentage) (F), showing fast and high peak enhancement followed by a marked 
washout (type 3 curves).
 There are various conditions that can mimic cancer on 
T2WI, such as prostatitis, hemorrhage, atrophy, benign 
hyperplasia, post–radiation therapy fibrosis and changes 
after hormone deprivation therapy. Although post-biopsy 
hemorrhage may mimic tumors on T2WI, it generally shows 
high signal intensity on T1WI, which does not happen with 
cancer. (Fig.s 6a, 6b). However, post-biopsy hemorrhage 
may hamper tumor detection and staging, by under or 
overestimating tumor presence and local extent, both 
on T2WI and on functional tools such as DCE and MRS. 
Since the usual abundant citrate in normal prostate has 
an anticoagulant effect, blood products may persist 4–6 
weeks or longer after prostate biopsy, so a delay of 6–8 
weeks after biopsy is usually recommended.1,2,7,16,21,24 Some 
authors recommend the acquisition of preliminary T1WI 
in order to exclude significant post-biopsy hemorrhage. If 
relevant hemorrhage is found, MRI examination may be 
rescheduled 3–4 weeks later.6
 In the evaluation of extracapsular extension (ECE), 
seminal vesicle invasion (SVI) and bladder neck invasion, 
high resolution T2WI in axial, coronal and sagittal planes 
should be used in combination. Sagittal images improve the 
evaluation of tumors located at the apex and base. ECE 
can be detected on T2WI by visualizing direct extension 
of the tumor into the periprostatic fat, but there are other 
criteria that include neurovascular bundle asymmetry, 
tumor envelopment of the neurovascular bundle, contour 
angulation, an irregular or speculated margin, obliteration of 
the rectoprostatic angle, capsular retraction, and evidence of 
direct tumor extension to the capsule (Fig.s 4a, 4b, 5a). MRI 
has been reported to have 13%–95% sensitivity and 49%–
97% specificity for detection of ECE. This huge variability 
may be related to the different expertise levels and technical 
protocols applied by distinct centers. The recent attempt on 
establishing clinical guidelines and optimal techniques is 
likely to achieve high and uniform sensitivity and specificity 
levels.3
 The features of SVI on MR images include the extension 
of tumor from the base of prostate, the presence of focal 
low signal intensity within the normal high signal seminal 
vesicles, disruption or loss of the normal SV architecture, 
enlarged low-signal-intensity ejaculatory ducts, enlarged 
low-signal intensity seminal vesicle and obliteration of the 
angle between the prostate and the seminal vesicle (Fig. 
5b). Sensitivity and specificity for detection of SVI are 
variable depending on the study, ranging from 20 to 80% 
and from 81 to 99%, respectively.1,3,7,25,26 
 The invasion of adjacent organs like bladder and rectum 
is also identified by MR imaging and optimized with sagittal 
imaging planes.21
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Figure 4 - Images in a 76-year-old man with PSA level of 15,6 ng/mL and biopsy-proven adenocarcinoma (Gleason score of 7). Axial and 
sagittal T2WI (A,B) show diffuse peripheral hypointensity (arrowheads) and a right basal prostate bulging compatible with extracapsular 
extension (arrows). This area demonstrates high signal intensity on high b-value DWI (C) and appears dark on corresponding ADC map 
(D) (arrows). DCE images (E,F) demonstrate fast and heterogeneous enhancement and highly suspicious, type 3, time-signal intensity 
curves. Pathological right para-rectal tumor deposits were also identified.
Dynamic contrast-enhanced (DCE) MR imaging
 The tumor angiogenesis and the characteristic 
surrounding interstitial environment can be used as a 
diagnostic marker of disease, altering the enhancement 
pattern after contrast administration.1,7,16 The cancerous 
tissue has an increased number of vessels due to the 
production and release of angiogenic factors (vascular 
permeability growth factor or vascular endothelial growth 
factor) and its permeability is greater than normal vessels. 
3,16,27,28 
 DCE MR imaging provides direct depiction of tumor 
vascularity. A full dose (0.1 mmol/ kg) of gadolinium is 
generally injected at 3 mL/sec, and serial 3D acquisitions 
are obtained every 2–5 seconds through the prostate. That 
way, it is possible to display quantitative kinetic parameters 
reflecting contrast washin and washout, including onset 
time, time to peak, peak enhancement, relative peak 
enhancement (comparing to normal tissue), and washout 
time.1,7,16,21 
 Tumors often demonstrate early nodular enhancement 
before the rest of the parenchyma and early washout 
of signal intensity, a pattern which is highly predictive of 
prostate cancer despite being non pathognomonic. This 
washout pattern corresponds to a type 3 enhancement 
curve. A type 2 enhancement curve (plateau) may be also 
associated to malignancy, while a type 1 (steadily rising) 
curve is unlikely malignant (Fig.s 2c-d, 3d-f, 4e-f).1,6,7,16,28 
 Engelbrecht et al27 demonstrated that the relative peak 
enhancement was the most accurate perfusion parameter 
for cancer detection in the peripheral zone and central 
region of the gland. The detection of areas of enhancement 
on early postcontrast images (within the first 30–60 seconds 
after contrast material injection) constitutes a qualitative 
feature and may also be used to detect cancer.21
 When carcinoma has spread throughout the prostate, 
normal prostatic tissue cannot be used as a reference 
and consequently it is not possible to use relative peak 
enhancement. In these cases, peak enhancement can be 
used as the parameter in the PZ, and washout can be used 
as the parameter in the CG. Peak enhancement is not ideal 
in CG because of the high peak enhancement levels usually 
found in normal CG tissue.27
 Some studies like that of Kim et al29 demonstrated that 
dynamic contrast-enhancement analysis was more accurate 
for the detection of prostate cancer in the peripheral zone 
than conventional T2-weighted imaging alone. DCE alone 
has reported variable sensitivity and specificity, ranging 
of 52–96% and 65–95%, respectively, which is probably 
related to different patient selection criteria, as well as 
distinct protocols and analytic techniques applied.3,9,30
 DCE MRI has an important limitation: the insufficient 
depiction of transitional zone cancer in patients with 
Lopes Dias J, et al. Prostate cancer: the role of multiparametric magnetic resonance imaging, Acta Med Port 2015 Mar-Apr;28(2):240-249
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Figure 5 - Images in 71-year-old man with PSA level of 12.6 ng/mL and biopsy-proven adenocarcinoma (Gleason score of 9). Unenhanced 
axial (A) and coronal (B) T2WI show a large hypointense tumor in the base of the prostate, with obliteration of the pseudocapsule and 
extension to the transition zone. There is also diffuse bulging and irregularity of the posterior prostate contour and mild, low-signal intensity 
enlargement of the seminal vesicles, findings highly suggestive of posterior ECE (arrowheads, a) and SVI (arrows, b). ADC map (C) shows 
diffuse low ADC values. Axial T2WI with fat-supression (D) shows bilateral hyperintense iliac bone metastasis (arrows).
hypervascular benign prostatic hyperplasia because 
abnormal enhancement patterns may be seen in both 
tumors and benign nodules.16,29 Moreover, smaller and low 
grade tumors may not demonstrate abnormal enhancement 
on DCE, and some prostate tumors are only mildly or 
moderately hypervascular, and thus are not detectable 
through this technique.16
 DCE MRI can also be used for the detection of post-
prostatectomy and post-radiotherapy recurrences, and 
for determining the effectiveness of hormone deprivation 
therapy, which tends to reduce the tumor permeability and 
to change the tissue washout pattern.6,16,28,31
Diffusion-weighted imaging (DWI) 
 DWI is a functional technique that assesses the random 
movement or Brownian motion of water molecules in different 
physical media through the use of MRI.15,32 The diffusion 
properties of a biological tissue are related to the amount 
of interstitial free water and permeability, reflecting tissue 
cellularity and the presence of intact cellular membranes. 
In general, cancer, abscesses, fibrosis, hemorrhage and 
cytotoxic edema may show restricted diffusion compared 
to than normal tissue, because of the high cellular density. 
In prostate cancer (particularly in the peripheral zone, 
more frequently studied), normal glandular architecture is 
disrupted and replaced by aggregated cancer cells and 
Lopes Dias J, et al. Prostate cancer: the role of multiparametric magnetic resonance imaging, Acta Med Port 2015 Mar-Apr;28(2):240-249
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Figure 6 - Images in 62-year-old man with PSA level of 6.54 ng/mL and biopsy-proven adenocarcinoma (Gleason score of 7). Axial T2WI 
(A) shows a moderately hypointense area within the left peripheral zone (open arrow). This area is hyperintense on T1WI (B), shows 
non-suspicious high signal on the ADC map (C) and demonstrates no relevant enhancement on DCE (D), corresponding to post-biopsy 
hemorrhage (open arrows). By contrast, a tumor is found within the right peripheral zone (arrows), showing marked hypointensity on T2WI 
(A), low ADC values (C), and strong enhancement on DCE (D).
fibrotic stroma, which constitutes an inhibitory environment 
to the movement of water.16,32,33 
 The differences in water diffusion rates between normal 
and tumoral tissues can be depicted and quantitatively 
represented by apparent diffusion coefficient (ADC) maps, 
which are obtained with at least two b values. Restricted 
diffusion typically seen in prostate cancer leads to high 
signal on raw high b value DWI and low signal intensity on 
ADC maps (Fig.s 3b-c, 4c-d, 5c).3,18
 The b value refers to the strength of the diffusion 
sensitizing gradient, which means that at a b value of 0 
sec/mm2 there’s no gradient. At low b value, free water 
molecules have high signal intensity and the signal intensity 
is based on T2 weighting. At high b values, such as 1000 
sec/mm2, only the water molecules with restricted diffusion 
retain their high signal and persist bright on DWI, as may 
occur within a tumour. There is no absolute consensus 
about the optimal b value for prostate cancer detection, 
but it is known that higher b values may increase diffusion 
sensitivity by lowering the normal hyperintensity of tissues 
with long T2 relaxation times, such as the PZ.32-35
 Several studies showed significant differences in the 
mean ADC values between cancerous and normal tissues 
for the PZ and to a lesser extent for the TZ (36). However, 
other studies showed considerable overlap of ADC values 
between prostate cancer and benign conditions like BPH and 
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prostatitis.16,18,34,37-44 There is also evidence of a significant 
negative correlation between the ADC values of prostate 
tumors and prostatectomy specimen Gleason scores. 
Bittencourt et al32 suggested that ADC values perform 
better than TRUS guided biopsy Gleason scores in the 
correlation with prostatectomy Gleason scores. However, 
individual variability may decrease the diagnostic accuracy 
of ADC measurement for prostate cancer detection and 
localization.16 
 According to Shimofusa et al,35 the use of DWI in 
addition to T2WI significantly improved the accuracy of 
tumor detection when compared to T2WI alone, with an 
area under the curve of 0.93 for the combined imaging 
techniques and 0.87 for T2WI alone. Moreover, adding DWI 
seems to significantly improve the accuracy of prostate 
peripheral tumor volume measurement.45
 The main advantage of DWI is the high contrast 
resolution between tumors (which appear bright) and 
normal tissue. Nevertheless, this technique is limited by 
susceptibility to hemorrhage, gas, peristalsis, and detrusor 
contraction artifacts. The lack of anatomical references is 
also limiting but may be overcome through the fusion of 
high b-value images and T2WI.16
Targeted prostate biopsies and active surveillance
 TRUS-guided prostate biopsy with 10-12 samples 
remains the gold standard for detecting prostate cancer. 
However, this standard technique has some limitations. 
First, it misses 30-40% of prostate tumors located in the 
anterior lateral peripheral zone, in the transition zone 
or in the anterior fibromuscular stroma. Second, it may 
miss significant cancer, even in the peripheral zone, and 
some non-clinically significant cancers (low volume and 
Gleason ≤ 6 tumors) may be diagnosed. Moreover, it may 
not accurately predict final Gleason score, since upgrading 
of apparently low-grade tumors found at TRUS biopsy is 
common at more definitive histology.13,46,47 In this set, one of 
the main goals of mp-MRI is to avoid some PSA only-driven 
random prostate biopsies, by localizing suspicious areas for 
further guided procedures.
 Multiparametric-MRI targeted prostate biopsies include 
cognitive fusion TRUS targeting, MRI-TRUS fusion targeting, 
and in-bore MRI-guided biopsy. Cognitive fusion targeting 
implies the review of MR images before the procedure by 
the biopsy performer. This operator dependent technique 
relies on the ability of the performer to mentally register 
the site considered on MRI at the time of TRUS biopsy. 
In addition, it shows an important disadvantage: several 
tumors are isoechogenic or only slightly hypoechogenic 
comparing to the surrounding gland, and therefore non 
visible by ultrasonography.46 Distinctly, MRI-TRUS fusion 
targeting is less operator-dependent, allowing a real-time 
fusion between US images and pre-biopsy MRI, so the 
target is visualized during the biopsy. MRI-guided biopsy 
is performed at the time of MRI and allows real-time MRI 
guidance. However, it is time consuming, expensive, implies 
MR compatible biopsy devices, and is probably associated 
with prostate deformation and higher patient discomfort.46
 By now, the strongest indication for pre-biopsy MRI 
targeting is probably previously negative biopsies despite 
ongoing clinical suspicion of prostate cancer. The current 
guidelines do not recommend targeted samples only, but 
many studies have been developed and this is a very 
promising research field that may significantly change the 
daily practice.48,49
 According to the ESUR guidelines, low risk patients 
(which are those with PSA ≤ 10 ng/mL, biopsy Gleason 
score ≤ 6, and clinical stage T1-T2a) are good candidates 
for active surveillance.6 The currently used clinical 
protocols take into account other inclusion criteria, namely 
less than 3 positive core biopsy fragments (in a minimum 
of 12) and less than 50% involvement of each fragment.50,51 
The main goal of active surveillance is to avoid radical 
treatment unless disease progresses or the patient decides 
to undergo treatment.10 Mp-MRI may firstly confirm the 
classification of risk status, by excluding unexpected larger, 
more aggressive, and higher-grade tumors.48,49 If the risk 
status is compatible, mp-MRI may be used to follow-up. 
Sometimes, the tumor is not visible and if it remains not 
seen in following MR examinations, it indicates that the 
development of a clinically significant cancer is implausible. 
When the tumor is initially identifiable, it may be monitored for 
change, according to several morphological and functional 
criteria. These criteria are not well established, since further 
research is needed, but the volume of the dominant focus, 
appearance of additional foci, changes on DCE pattern, and 
decreases on ADC values should be checked.6
 Figure 7 summarizes the role of mp-MRI on prostate 
cancer, including detection with targeted biopsies and 
active surveillance. 
 
CONCLUSION
 Multiparametric MRI combines conventional T1WI 
and high-resolution T2WI with at least two functional 
techniques, including DCE and DWI. T2WI is a water-
sensitive sequence used for tumor detection and T1WI 
is blood-sensitive, allowing the recognition of post-biopsy 
hemorrhage, which may compromise diagnosis. DCE 
assesses tumor vascularity and DWI detects areas of 
restriction to the diffusion of water molecules, namely by 
tightly packed tumor cells.
 The role of mp-MRI in prostate cancer has been 
recently studied and is continually improving both clinically 
significant disease detection and staging. It is hoped that 
recent progress on technique may contribute to decrease 
prostate cancer mortality and morbidity by allowing better 
early diagnosis, and better patient selection for focused 
radiotherapy, focal ablative therapy, prostate sparing 
surgery and active surveillance. However, more studies are 
needed to compare the functional techniques, understand 
the advantages and disadvantages of each one and to 
assess the overall impact of MP-MR on patient outcome.
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Figure 7 -Role of Multiparametric MRI on Prostate Cancer.
OBSERVATIONS
 Please consider this manuscript of our work, which was 
presented in part at the XXIII International Symposium on 
Morphological Sciences, in Niigata (September 2013).
CONFLICT OF INTERESTS
 None stated.
FUNDING SOURCES
 None stated.
REFERENCES
1. Ravizzini G, Turkbey B, Kurdziel K, Choyke PL. New horizons in prostate 
cancer imaging. Eur J Radiol. 2009;70:212–26. 
2. Chabanova E, Balslev I, Logager V, Hansen A, Jakobsen H, Kromann-
Andersen B, et al. Prostate cancer: 1.5 T endo-coil dynamic contrast-
enhanced MRI and MR spectroscopy--correlation with prostate biopsy 
and prostatectomy histopathological data. Eur J Radiol. 2011;80:292–6.
3. Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized 
prostate cancer: current approaches and new developments. AJR Am J 
Roentgenol. 2009;192:1471–80. 
4. Hegde JV, Mulkern RV, Panych LP, Fennessy FM, Fedorov A, Maier SE, 
et al. Multiparametric MRI of prostate cancer: an update on state-of-the-
art techniques and their performance in detecting and localizing prostate 
cancer. J Magn Reson Imaging. 2013;37:1035–54. 
5. Talab SS, Preston MA, Elmi A, Tabatabaei S. Prostate cancer imaging: 
what the urologist wants to know. Radiol Clin North Am. 2012;50:1015–
41.
6. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, 
et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22:746–57.
7. Hricak H, Choyke P, Eberhardt SC, Leibel SA, Scardino PT. Imaging 
Prostate Cancer: a multidisciplinary perspective. Radiology. 
2007;243:28–53.
8. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, 
et al. Scoring systems used for the interpretation and reporting of 
multiparametric MRI for prostate cancer detection, localization, and 
characterization: could standardization lead to improved utilization 
of imaging within the diagnostic pathway? J Magn Reson Imaging. 
2013;37:48–58. 
9. Cheikh AB, Girouin N, Colombel M, Maréchal JM, Gelet A, Bissery 
A, et al. Evaluation of T2-weighted and dynamic contrast-enhanced 
MRI in localizing prostate cancer before repeat biopsy. Eur Radiol. 
2009;19:770–8.
10. Turkbey B, Mani H, Aras O, Ho J, Hoang A, Rastinehad AR, et al. 
Prostate cancer: can multiparametric MR imaging help identify patients 
who are candidates for active surveillance? Radiology. 2013;268:144–
52.
11. Jung A, Westphalen A. Imaging prostate cancer. Radiol Clin North Am 
Am. 2012;50:1043–59.
12. Futterer JJ. Imaging of recurrent prostate cancer. Radiol Clin North Am 
Am. 2012;50:1075–83.
13. Haffner J, Lemaitre L, Puech P, Haber GP, Leroy X, Jones JS, et al. 
Role of magnetic resonance imaging before initial biopsy: comparison 
of magnetic resonance imaging-targeted and systematic biopsy for 
significant prostate cancer detection. BJU Int. 2011;108:E171–8.
14. Shimizu T, Nishie A, Ro T, Tajima T, Yamaguchi A, Kono S, et al. Prostate 
cancer detection: the value of performing an MRI before a biopsy. Acta 
Radiol. 2009;50:1080–8.
15. Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF, Carroll PR, 
et al. Evaluating localized prostate cancer and identifying candidates for 
focal therapy. Urology. 2008;72:S12–24.
16. Choi YJ, Kim JK, Kim N, Kim KW, Choi EK, Cho K-S. Functional MR 
imaging of prostate cancer. RadioGraphics. 2007;27:63–75.
17. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, 
et al. Prostate cancer: localization with three-dimensional proton 
MR spectroscopic imaging-clinicopathologic study. Radiology. 
1999;213:473–80.
18. Chen M, Dang HD, Wang JY, Zhou C, Li SY, Wang WC, et al. Prostate 
cancer detection: comparison of T2-weighted imaging, diffusion-
weighted imaging, proton magnetic resonance spectroscopic imaging, 
and the three techniques combined. Acta Radiol. 2008;49:602–10.
19. Heijmink S, Futterer JJ, Hambrock T, Takahashi S, TW S, Huisman HJ. 
Prostate cancer: body-array versus endorectal coil MR imaging at 3 
T—comparison of image quality, localization, and staging performance. 
Radiology. 2007;244:184–95.
20. Fütterer JJ, Engelbrecht MR, Jager GJ, Hartman RP, King BF, 
Hulsbergen-Van de Kaa CA, et al. Prostate cancer: comparison of local 
staging accuracy of pelvic phased-array coil alone versus integrated 
endorectal-pelvic phased-array coils. Local staging accuracy of prostate 
cancer using endorectal coil MR imaging. Eur Radiol. 2007;17:1055–65.
21. Claus FG, Hricak H, Hattery RR. Pretreatment evaluation of prostate 
cancer : role of MR imaging and 1H MR spectroscopy. Radiographics. 
DETECTION
STAGING
ACTIVE 
SURVEILLANCE
RECURRENCE
SUSPITION
• US fusion biopsy
• MRI-guided biopsy
• Tumor size
• ADC value
• DCE pattern
• Local
• Nodal
• Bone
• Prostatectomy
• Radiation
Lopes Dias J, et al. Prostate cancer: the role of multiparametric magnetic resonance imaging, Acta Med Port 2015 Mar-Apr;28(2):240-249
A
R
TI
G
O
 D
E 
R
EV
IS
Ã
O
Revista Científica da Ordem dos Médicos          www.actamedicaportuguesa.com                                                                                                                249
2004;24:167–80.
22. Akin O, Sala E, Moskowitz CS, Kuroiwa K, Ishill NM, Pucar D, et al. 
Transition zone prostate cancers: features, detection, localization, and 
staging at endorectal MR Imaging. Radiology. 2006;239:784–92.
23. Chesnais AL, Niaf E, Bratan F, Mège-Lechevallier F, Roche S, 
Rabilloud M, et al. Differentiation of transitional zone prostate cancer 
from benign hyperplasia nodules: evaluation of discriminant criteria at 
multiparametric MRI. Clin Radiol. 2013;68:e323–30.
24. Tamada T, Sone T, Jo Y, Yamamoto A, Yamashita T, Egashira N, et al. 
Prostate Cancer: relationships between postbiopsy hemorrhage and 
tumor detectability at MR diagnosis. Radiology. 2008;248:531–9.
25. Soylu FN, Peng Y, Jiang Y, Wang S, Schmid-Tannwald C, Sethi I, et 
al. Seminal vesicle invasion in prostate cancer: evaluation by using 
multiparametric endorectal MR imaging. Radiology. 2013;267:797–806.
26. Kim B, Kawashima A, Ryu J, Takahashi N, Hartman RP. Imaging of the 
seminal vesicle and vas deferens. Radiographics. 2009;29:1105–21.
27. Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, 
Hulsbergen-Van De Kaa CA, et al. Discrimination of prostate cancer 
from normal peripheral zone and central gland tissue by using dynamic 
contrast-enhanced MR imaging. Radiology. 2003;229:248–54.
28. Alonzi R, Padhani A, Allen C. Dynamic contrast enhanced MRI in 
prostate cancer. Eur J Radiol. 2007;63:335–50.
29. Kim JK, Hong SS, Choi YJ, Park SH, Ahn H, Kim CS, et al. Wash-in 
rate on the basis of dynamic contrast-enhanced MRI: usefulness for 
prostate cancer detection and localization. J Magn Reson Imaging. 
2005;22:639–46.
30. Jager GJ, Ruijter ET, van de Kaa CA, de la Rosette JJ, Oosterhof 
GO, Thornbury JR, et al. Dynamic TurboFLASH subtraction technique 
for contrast-enhanced MR imaging of the prostate: correlation with 
histopathologic results. Radiology. 1997;203:645–52.
31. Del Vescovo R, Pisanti F, Russo V, Battisti S, Cazzato RL, D’Agostino 
F, et al. Dynamic contrast-enhanced MR evaluation of prostate cancer 
before and after endorectal high-intensity focused ultrasound. Radiol 
Med. 2013;118:851–62.
32. Bittencourt LK, Barentsz JO, de Miranda LC, Gasparetto EL. 
Prostate MRI: diffusion-weighted imaging at 1.5T correlates better 
with prostatectomy Gleason Grades than TRUS-guided biopsies in 
peripheral zone tumours. Eur Radiol. 2012;22:468–75.
33. Qayyum A. Diffusion-weighted imaging in the abdomen and pelvis: 
concepts and applications. Radiographics. 2009;29:1797–810.
34. Sato C, Naganawa S, Nakamura T, Kumada H, Miura S, Takizawa 
O, et al. Differentiation of noncancerous tissue and cancer lesions by 
apparent diffusion coefficient values in transition and peripheral zones 
of the prostate. J Magn Reson Imaging. 2005;21:258–62.
35. Shimofusa R, Fujimoto H, Akamata H, Motoori K, Yamamoto S, Ueda 
T, et al. Diffusion-weighted imaging of prostate cancer. J Comput Assist 
Tomogr. 2005;29:149–53.
36. Hoeks CM, Hambrock T, Yakar D, Hulsbergen-van de Kaa CA, 
Feuth T, Witjes JA, et al. Transition zone prostate cancer: detection 
and localization with 3-T multiparametric MR imaging. Radiology. 
2013;266:207–17.
37. Nagel KN, Schouten MG, Hambrock T, Litjens GJ, Hoeks CM, ten 
Haken B, et al. Differentiation of prostatitis and prostate cancer by using 
diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology. 
2013;267:164–72.
38. Watanabe Y, Nagayama M, Araki T, Terai A, Okumura A, Amoh Y, et al. 
Targeted biopsy based on ADC map in the detection and localization 
of prostate cancer: a feasibility study. J Magn Reson Imaging. 
2013;37:1168–77. 
39. Vargas HA, Akin O, Franiel T, Mazaheri Y, Zheng J, Moskowitz C et al. 
Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: 
tumor detection and assessment of aggressiveness. Radiology. 
2011;259:775–84.
40. Turkbey B, Shah VP, Pang Y, Bernardo M, Xu S, Kruecker J, et al. 
Is apparent diffusion coefficient associated with clinical risk scores 
for prostate cancers that are visible on 3-T MR images? Radiology. 
2011;258:488–95.
41. Hambrock T, Somford DM, Huisman HJ, van Oort I, Witjes JA, 
Hulsbergen-Van de Kaa C. Relationship between apparent diffusion 
coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone 
prostate cancer. Radiology. 2013;259:453–61.
42. Kitajima K, Takahashi S, Ueno Y, Miyake H, Fujisawa M, Kawakami F, 
et al. Do apparent diffusion coefficient (ADC) values obtained using high 
b-values with a 3-T MRI correlate better than a transrectal ultrasound 
(TRUS)-guided biopsy with true Gleason scores obtained from radical 
prostatectomy specimens for patients with prostat. Eur J Radiol. 
2013;82:1219–26.
43. DeSouza N, Riches S, Vanas N, Morgan V, Ashley S, Fisher C. Diffusion-
weighted magnetic resonance imaging: a potential non-invasive marker 
of tumour aggressiveness in localized prostate cancer. Clin Radiol. 
2008;63:774–82.
44. Verma S, Rajesh A, Morales H, Lemen L, Bills G, Delworth M, et 
al. Assessment of aggressiveness of prostate cancer: correlation 
of apparent diffusion coefficient with histologic grade after radical 
prostatectomy. AJR Am J Roentgenol. 2011;196:374–81. 
45. Mazaheri Y, Hricak H, Fine S, Akin O, Shukla-Dave A, Ishill NM. Prostate 
tumor volume measurement with combined T2-weighted imaging and 
diffusion-weighted MR: correlation with pathologic tumor volume. 
Radiology. 2009;252:449–57.
46. Ghai S, Toi A. Role of transrectal ultrasonography in prostate cancer. 
Radiol Clin N Am. 2012;50:1061–73.
47. Margel D, Yap SA, Lawrentschuk N, Klotz L, Haider M, Hersey K, et al. 
Impact of multiparametric endorectal coil prostate magnetic resonance 
imaging on disease reclassification among active surveillance 
candidates: a prospective cohort study. J Urol. 2012;187:47–1252.
48. Kirkham AP, Haslam P, Keanie JY, McCafferty I, Padhani AR, Punwani S, 
et al. Prostate MRI: who, when, and how? Report from a UK consensus 
meeting. Clin Radiol. 2013;68:1016–23.
49. Ahmed H, Kirkham A, Arya M, Illing R, Freeman A. Is it time to consider 
a role for MRI before prostate biopsy? Nat Rev Clin Oncol. 2009;6:197–
206.
50. Lawrentschuk N, Klotz L. Active surveillance for low-risk prostate cancer: 
an update. Nat Rev Urol. 2011;8:312–20.
51. Large M, Eggener S. Active surveillance for low-risk localized prostate 
cancer. Oncology. 2009;23:974–9. 
Lopes Dias J, et al. Prostate cancer: the role of multiparametric magnetic resonance imaging, Acta Med Port 2015 Mar-Apr;28(2):240-249
João LOPES DIAS, João MAGALHÃES PINA, Raquel JOÃO, Joana FIALHO, Sandra CARMO, Cecília LEAL,  
Tiago BILHIM, Rui MATEUS MARQUES, Luís CAMPOS PINHEIRO
Prostate Cancer: The Role of Multiparametric 
Magnetic Resonance Imaging  
Acta Med Port 2015:28:240-249
Publicado pela Acta Médica Portuguesa, a Revista Científica da Ordem dos Médicos
Av. Almirante Gago Coutinho, 151 
1749-084 Lisboa, Portugal. 
Tel: +351 218 428 215 
E-mail: submissao@actamedicaportuguesa.com
www.actamedicaportuguesa.com
ISSN:0870-399X | e-ISSN: 1646-0758
